Acadia Pharmaceuticals (ACAD)
Develops NUPLAZID and DAYBUE for neurological and rare diseases.
$26.41
After hours+0.00 (+0.02%)
At close$26.41(+0.04%)
Something off on this page? Send us feedback.
Next report
Nov 4, 26
in 43 days
EPS estimate
$0.21
Revenue estimate
$332.3M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$0.86$0.11$0.16$0.42$1.60$0.02$0.18Pending
Estimate$0.19$0.10$0.14$0.14$0.14$0.04$0.07$0.21
Surprise+352.6%+10.0%+14.3%+200.0%+1,067.9%−50.0%+164.1%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$259.6M$244.3M$264.6M$278.6M$284.0M$268.1M$308.0MPending
Estimate$255.6M$239.0M$262.0M$276.5M$292.8M$280.3M$296.6M$332.3M
Surprise+1.6%+2.2%+1.0%+0.8%−3.0%−4.3%+3.8%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | $0.41 | — | — |
| Sep 2027 | $0.27 | — | — |
| Jun 2027 | $0.25 | — | — |
| Mar 2027 | $0.21 | — | — |
| Dec 2026 | $0.22 | — | — |
| Nov 2026 | $0.21 | — | — |
| Aug 2026 | $0.07 | $0.18 | +164.1% |
| May 2026 | $0.04 | $0.02 | −50.0% |
| Feb 2026 | $0.14 | $1.60 | +1,067.9% |
| Nov 2025 | $0.14 | $0.42 | +200.0% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Oct 2019 | |||
| Jul 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | $0.41 | — | — | $418.1M | — | — | — |
| Sep 2027 | $0.27 | — | — | $396.5M | — | — | — |
| Jun 2027 | $0.25 | — | — | $369.7M | — | — | — |
| Mar 2027 | $0.21 | — | — | $350.2M | — | — | — |
| Dec 2026 | $0.22 | — | — | $363.2M | — | — | — |
| Nov 4, 2026 | $0.21 | — | — | $332.3M | — | — | — |
| Aug 4, 2026 | $0.07 | $0.18 | +164.1% | $296.6M | $308.0M | +3.8% | +6.1% |
| May 6, 2026 | $0.04 | $0.02 | −50.0% | $280.3M | $268.1M | −4.3% | +5.0% |
| Feb 25, 2026 | $0.14 | $1.60 | +1,067.9% | $292.8M | $284.0M | −3.0% | −1.3% |
| Nov 5, 2025 | $0.14 | $0.42 | +200.0% | $276.5M | $278.6M | +0.8% | −3.1% |
| Aug 6, 2025 | |||||||
| May 7, 2025 | |||||||
| Feb 26, 2025 | |||||||
| Nov 6, 2024 | |||||||
| Aug 6, 2024 | |||||||
| May 8, 2024 | |||||||
| Feb 27, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 2, 2023 | |||||||
| May 8, 2023 | |||||||
| Feb 27, 2023 | |||||||
| Nov 2, 2022 | |||||||
| Aug 8, 2022 | |||||||
| May 4, 2022 | |||||||
| Feb 28, 2022 | |||||||
| Nov 8, 2021 | |||||||
| Aug 4, 2021 | |||||||
| May 5, 2021 | |||||||
| Feb 24, 2021 | |||||||
| Nov 4, 2020 | |||||||
| Aug 5, 2020 | |||||||
| May 7, 2020 | |||||||
| Feb 26, 2020 | |||||||
| Oct 30, 2019 | |||||||
| Jul 31, 2019 | |||||||
| May 1, 2019 | |||||||
| Feb 26, 2019 | |||||||
| Nov 6, 2018 | |||||||
| Aug 8, 2018 | |||||||
| May 4, 2018 | |||||||
| Feb 27, 2018 | |||||||
| Nov 7, 2017 | |||||||
| Aug 8, 2017 | |||||||
| May 9, 2017 | |||||||
| Feb 28, 2017 | |||||||
| Nov 7, 2016 | |||||||
| Aug 4, 2016 | |||||||
| May 5, 2016 | |||||||
| Feb 29, 2016 | |||||||
| Nov 5, 2015 | |||||||
| Aug 6, 2015 |